Tango Therapeutics, Inc. — Director's Dealing 2021

Aug 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tango Therapeutics, Inc. (TNGX)
CIK: 0001819133
Period of Report: 2021-08-12

Reporting Person: Weber Barbara (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-12	Stock Option (Right to Buy)	$9.56	A	961403	Acquired	2031-08-12	Common Stock (961403)	Direct

Footnotes

F1: This option shall vest and become exercisable over a four-year period, at a rate of 25% on August 10, 2022, with the remaining option shares vesting in 36 equal monthly installments thereafter.